Persistent Asset Partners’s Terns Pharmaceuticals TERN Stock Holding History

Persistent Asset Partners’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-45,953	Closed	-$2.42M	–	906
2026 Q1	$2.42M	Sell	45,953 -67,602	-60%	-$2.78M	0.9%	26
2025 Q4	$4.59M	Buy	113,555 +39,190	+53%	+$906K	2.06%	6
2025 Q3	$558K	Buy	74,365 +14,568	+24%	+$93K	0.38%	80
2025 Q2	$223K	Buy	59,797 +46,990	+367%	+$147K	0.17%	110
2025 Q1	$35.3K	Hold	12,807	–	–	0.03%	140
2024 Q4	$57.1K	Buy	+12,807	New	+$86.7K	0.05%	113

Other funds holding TERN

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Persistent Asset Partners's TERN Position: Q2 2026 in Review

Persistent Asset Partners sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 45,953 shares — an estimated $2.42M sold.

Persistent Asset Partners first reported a position in TERN in Q4 2024 and held it in 6 quarters. The position peaked at $4.59M in Q4 2025. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Persistent Asset Partners reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Persistent Asset Partners sold 45,953 Terns Pharmaceuticals shares in Q2 2026, an estimated $2.42M.
Persistent Asset Partners first reported a position in Terns Pharmaceuticals in Q4 2024 and held it in 6 quarters.
Persistent Asset Partners's Terns Pharmaceuticals position peaked at $4.59M in Q4 2025.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.